Informations générales (source: ClinicalTrials.gov)
Study of the Angiogenesis Measured by PET/CT With 18F-RGD-K5 in Patients With Lymphoma : a Preliminary Study (RGDLymphome)
Interventional
Phase 2
Centre Henri Becquerel (Voir sur ClinicalTrials)
novembre 2015
mai 2020
29 juin 2024
The aim of the study is to measure tumoral angiogenesis modifications by RGD-K5 PET/CT
before and after 2 cycles of chemotherapy in patients with lymphoma and a large tumoral
mass
Etablissements
| Les établissements hors Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| Centre Henri Becquerel - 76038 - Rouen - France | Pierre Vera, MD,PhD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Male or Female
- Age ≥ 18 years old
- OMS ≤ 1
- Histological diagnosis of diffuse large B-cell lymphoma what ever the subtype
- Presence of measurable tumor with at least a node mass superior to 3 centimeters
- Stage I to IV
- Inform consent signed
- Male or Female
- Age ≥ 18 years old
- OMS ≤ 1
- Histological diagnosis of diffuse large B-cell lymphoma what ever the subtype
- Presence of measurable tumor with at least a node mass superior to 3 centimeters
- Stage I to IV
- Inform consent signed
- Primary cerebral lymphoma
- Absence of fixing on FDG-PET exam
- Pregnant , child bearing, breast feeding or without effective contraception method
woman
- Hypersensitivity to RGD-K5
- Hypersensitivity to FDG
- Poorly controlled diabètes (glycemia ≥ 10 millimoles/liter)
- Neoplastic disease (less than 2 years or in progression)